TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04435353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibroLUNG
Description: Lungs intensive therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibroLUNG
Description: Lungs intensive therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibroLUNG
Description: Lungs intensive therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibroLUNG
Description: Lungs intensive therapy
Study: NCT01184183

Intervention type: PROCEDURE
Intervention: Comparing Accuseal Vs. Bovine Pericardial in CEA
Description: Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis.

Intervention type: PROCEDURE
Intervention: Comparing Accuseal Vs. Bovine Pericardial in CEA
Description: Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis.
Study: NCT01392794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, without water
Study: NCT03409367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream
Description: Lipid-rich emollient serving as skin barrier
Study: NCT04011410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200Mg Tab
Description: Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
Study: NCT00796653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Study: NCT00315562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid endarterectomy
Study: NCT02436447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
Study: NCT02308475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatom Force CT Scanner
Description: Dynamic CT perfusion of the heart
Study: NCT03023150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT01776190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA1 radiation treatment
Study: NCT02570009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEAMS (Talking about Eating, Activity, Mutual Support)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEAMS (Talking about Eating, Activity, Mutual Support)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Need Support Training
Study: NCT06456918

Intervention type: PROCEDURE
Intervention: Quality of Recovery 15 questionnaire
Description: return to daily life after surgery according to the patient's baseline or social norms
Study: NCT01346735

Intervention type: OTHER
Intervention: No intervention
Study: NCT00879918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated nicotine and cotinine
Description: used as a marker for pharmacokinetic studies
Study: NCT04019951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-propionate 1 g
Description: 1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-propionate 3 g
Description: 3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
Study: NCT03217539

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging
Study: NCT00697476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan, vorinostat
Description: Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal.
Study: NCT03708458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin suppository
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin suppository
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin suppository
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Study: NCT03575234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo surgery
Study: NCT00857103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICE
Description: Use of Choice support system as preparation for patient consultations
Study: NCT01401803

Intervention type: DRUG
Group type: OTHER
Intervention: Dysport
Description: Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
Study: NCT02045472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00800514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine
Description: amantadine 100 mg twice daily
Study: NCT03087552

Intervention type: PROCEDURE
Intervention: Transradial balloon aortic valvuloplasty
Description: Mini-invasive balloon aortic valvuloplasty consisting in transradial access

Intervention type: PROCEDURE
Intervention: Transradial balloon aortic valvuloplasty
Description: Rapid pacing using the 0.035-in. retrograde left ventricular support wire
Study: NCT03016637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SharkCore (TM) FNB Exchange System
Study: NCT05186155

Intervention type: PROCEDURE
Intervention: Severe ROP
Description: The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.

Intervention type: PROCEDURE
Intervention: Severe ROP
Description: The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.

Intervention type: PROCEDURE
Intervention: Severe ROP
Description: The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
Study: NCT01744821

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Vitamin D3 Group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02997670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithmic Cardiac Resynchronisation Therapy Optimisation
Description: Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
Study: NCT01060176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study: NCT02751905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered orally as specified in treatment arm
Study: NCT00778180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide 80 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide 80 mg tablets
Study: NCT00590473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interstim
Description: Unilateral vs. Bilateral Placement of Interstim IPG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interstim
Description: Unilateral vs. Bilateral Placement of Interstim IPG
Study: NCT04211896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
Study: NCT02859116

Intervention type: PROCEDURE
Intervention: Collection of digestive tissues
Description: The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
Study: NCT03695588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham QLB
Description: Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
Study: NCT01355367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Description: BAYA1040 CR 40mg BID
Study: NCT00757900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MUTAGRIP
Description: Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
Study: NCT04094480

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymeric non absorbable clips
Description: a method to secure appendicular stump

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endoloops
Description: a method to secure appendicular stump
Study: NCT01279993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kerato refractive Surgery
Description: This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
Study: NCT04469283

Intervention type: OTHER
Intervention: caffeine and movement disorders
Description: Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
Study: NCT04017455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 3 cycles of atezolizumab 840 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 3 cycles of bevacizumab 5mg/kg
Study: NCT01931605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic arterial embolization using BeadBlock (Terumo)
Description: Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
Study: NCT00520000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: 75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 180mg/m2 - 340mg/m2, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
Study: NCT04412187

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-GE-180 PET
Description: serial \[18F\]-GE-180 PET imaging to assess microglia activation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3T MRI
Description: serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: immune cell profiling in blood
Description: Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
Study: NCT02210754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes
Study: NCT04213131

Intervention type: OTHER
Group type: OTHER
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
Study: NCT00687518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Intravenous injection of 50 U/kg of erythropoietin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of equivalent volume of saline serum